Quick Answer
Ernexa Therapeutics Inc. reported Diluted EPS of $2.24 per share (loss) for fiscal year 2025.
Ernexa Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.24 | +95.4% |
| 2024 | -$48.96 | -1100.0% |
| 2023 | -$4.08 | +49.4% |
| 2022 | -$8.06 | +85.8% |
| 2021 | -$56.61 | -3649.0% |
| 2020 | -$1.51 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.15 | +99.8% | +75.4% |
| June 30, 2025 | -$0.61 | +96.0% | -306.7% |
| March 31, 2025 | -$0.15 | +87.8% | +99.8% |
| September 30, 2024 | -$73.70 | -7055.3% | -380.4% |
| June 30, 2024 | -$15.34 | -1704.7% | -1147.2% |
| March 31, 2024 | -$1.23 | -16.0% | -19.4% |
| September 30, 2023 | -$1.03 | +58.6% | -21.2% |
| June 30, 2023 | -$0.85 | +26.7% | +19.8% |
- Ernexa Therapeutics Inc. showed an increase of +95.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Ernexa Therapeutics Inc.’s diluted eps has declined by 48.3% (from $1.51 per share (loss) to $2.24 per share (loss)).
- The most recent figure is from Ernexa Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: